Coherus Oncology (CHRS) Operating Expenses (2013 - 2026)

Coherus Oncology has disclosed Operating Expenses across 14 years of filings, most recently posting $46.6 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 16.33% year-over-year to $46.6 million; the TTM figure through Jun 2026 stood at $209.6 million (down 2.41% YoY), while the FY2025 annual figure was $223.3 million, down 1.21% from the prior year.
• Operating Expenses came in at $46.6 million for Q2 2026 at Coherus Oncology, down from $48.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $160.4 million in Q4 2023 to a low of $46.6 million in Q2 2026.
• Average Operating Expenses over 5 years is $81.8 million, with a median of $64.4 million recorded in 2024.
• Year-over-year, Operating Expenses soared 65.66% in 2023 and slumped 66.89% in 2024.
• Over 5 years, Operating Expenses stood at $96.8 million in 2022, then jumped by 65.66% to $160.4 million in 2023, then tumbled by 66.89% to $53.1 million in 2024, then increased by 10.38% to $58.6 million in 2025, then fell by 20.45% to $46.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $46.6 million in Q2 2026, $48.5 million in Q1 2026, and $58.6 million in Q4 2025.